Lunit Makes Full-Fledged Entry into the Middle East with Participation in ‘Saudi Vision 2030’ Healthcare Transformation Project

Lunit's AI-powered cancer screening solutions have been selected for Seha Virtual Hospital's AI evaluation and clinical integration project.Successful validation to be followed by supply contract to assist Saudi Arabia's national cancer and tuberculosis screening program.

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the collaboration with Seha Virtual Hospital (SVH) in Riyadh, Kingdom of Saudi Arabia. The partnership seeks to contribute to driving healthcare transformation across Saudi Arabia, aligning with the Kingdom’s ‘Saudi Vision 2030’ strategy.

Under the project, Lunit has successfully delivered Lunit INSIGHT CXR, its AI solution for chest x-ray image analysis, and Lunit INSIGHT MMG, an AI solution for mammography analysis, to Seha Virtual Hospital for validation and integration purposes.

After the ongoing evaluation to confirm potential clinical benefits, both solutions are expected to be rolled out to more than 170 medical sites throughout Saudi Arabia as part of the national cancer and tuberculosis screening program.

Established in 2022, Seha Virtual Hospital is a cornerstone of the Kingdom’s healthcare innovation, which is the key initiative of the ‘Saudi Vision 2030’. As the world’s largest virtual hospital and the first of its kind in the Middle East, SVH plays a pivotal role in supporting 170 hospitals and providing medical services to 480,000 patients annually.

By integrating Lunit INSIGHT suite into their virtual cancer screening workflow, Seha Virtual Hospital aims to offer advanced examinations for patients and enhance the effectiveness of the national cancer screening program.

During the recent Hajj season, which took place from June 26 to July 1 and attracted 2 million pilgrims from 160 countries, Seha Virtual Hospital utilized Lunit INSIGHT CXR to detect chest abnormalities and prevent their spread.

“We are delighted to partner with Seha Virtual Hospital and contribute to the transformation of cancer diagnosis in Saudi Arabia,” said Brandon Suh, CEO of Lunit. “Given that Saudi Arabia boasts the largest medical market in the Gulf Cooperation Council, our highly promising partnership allows us to tap into this growing market. Through this collaboration, we aim to bring our innovative AI-powered solutions to healthcare providers throughout the Middle East, ultimately improving patient outcomes and making a significant impact on the fight against cancer.”

Lunit is actively extending its reach in the national cancer screening business through its collaboration with Seha Virtual Hospital, building upon the successful partnerships with Australia’s BreastScreen New South Wales (BSNSW) program last year and Capio St. Göran Hospital in Sweden earlier this year.

SourceLunit

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”